Asthma Therapeutic with IL-6 inhibitor
DE602019083668T2Active Publication Date: 2026-04-15KATO MOTOKAZU KISHIWADA-SHI
View PDF 0 Cites 0 Cited by
Patent Information
- Authority / Receiving Office
- DE · DE
- Patent Type
- Patents
- Current Assignee / Owner
- KATO MOTOKAZU KISHIWADA-SHI
- Filing Date
- 2019-01-31
- Publication Date
- 2026-04-15
AI Technical Summary
Technical Problem
Current treatments for severe asthma, including high-dose inhaled corticosteroids and biological formulations, often fail to control symptoms, leading to refractory asthma, and there is a lack of evidence that IL-6 inhibitors effectively improve asthma in humans.
Method used
A therapeutic agent containing an IL-6 inhibitor, such as an anti-IL-6 receptor antibody, is administered to treat non-eosinophilic severe asthma, suppressing exacerbations and improving quality of life.
Benefits of technology
The IL-6 inhibitor reduces asthma exacerbations and improves respiratory function and quality of life in patients with severe asthma, even in those who do not respond to conventional treatments.
✦ Generated by Eureka AI based on patent content.
Need to check novelty before this filing date? Find Prior Art
No text content released.